The Ocular Hypertension Treatment Study: Intraocular Pressure Lowering Prevents the Development of Glaucoma, but Does That Mean We Should Treat before the Onset of Disease?

Archives of Ophthalmology

Volumn 122, Issue 3, 2004, Pages 376-378

  Robin, Alan L ^a   Frick, Kevin D ^a   Katz, Joanne ^a   Budenz, Donald ^a   Tielsch, James M ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; TIMOLOL MALEATE;

BLINDNESS; CLINICAL PRACTICE; CLINICAL TRIAL; CORNEA; COST BENEFIT ANALYSIS; DRUG CONTRAINDICATION; DRUG COST; GLAUCOMA; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEDICAL DECISION MAKING; OPEN ANGLE GLAUCOMA; OPTIC NERVE LESION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; THICKNESS; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

ANTIHYPERTENSIVE AGENTS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; RISK FACTORS;

EID: 1542348335     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.3.376     Document Type: Review

References (19)

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
2. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
3. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000; 130:429-440.
4. Lichter PR, Musch DC, Gillespie BW, et al, and the CIGTS Study Group. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108: 1943-1953.
5. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
6. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991;134: 1102-1110.
7. Katz J, Gilbert D, Quigley HA, Sommer A. Estimating progression of visual field loss in glaucoma. Ophthalmology. 1997;104:1017-1025.
8. Smith SD, Katz J, Quigley HA. Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci. 1996;37: 1419-1428.
9. Quigley HA, Tielsch JM, Katz J, Sommer A. The rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol. 1996;122:355-363.
10. Rahmani B, Tielsch JM, Katz J, et al. The cause-specific prevalence of visual impairment in an urban population. Ophthalmology. 1996;103:1721-1726.
11. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma: the Beaver Dam Eye Study. Ophthalmology. 1992;99:1499-1504.
12. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980;24: 335-610.
13. Gutierrez P, Wilson MR, Johnson C, et al. Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol. 1997;115: 777-784.
14. Parrish RK II, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. 1997;115:1447-1455.
15. Jampel HD, Schwartz GF, Robin AL, Abrams D, Johnson E, Miller RB. Patient preferences for eyedrop characteristics a willingness-to-pay analysis. Arch Ophthalmol. 2003;121:540-546.
16. Nease RF, Whitcup SM, Ellwein LB, Fox G, Littenberg B. Utility-based estimates of the relative morbidity of visual impairment and angina. Ophthalmic Epidemiol. 2000;7:169-185.
17. Novack GD, O'Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population efficacy and safety. J Am Geriatr Soc. 2002;50:956-962.
18. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO, for the Ocular Hypertension Treatment Study Group. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2000;118:1187-1194.
19. Katz J, Quigley HA, Sommer A. Detection of incident field loss using the Glaucoma Hemifield Test. Ophthalmology. 1996;103:657-663.